Alzheimer s & Dementia · 2023 · 21 citations · 48 references
Life SciencesNeurologyNeuroscienceDementiaNeurodegenerationNeuroimmunologyAlzheimer DiseaseCerebrospinal Fluid BiomarkersDementia BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationAlzheimer Disease Vascular PathologyCerebrospinal Fluid Inflammatory BiomarkersNeuroinflammation In Alzheimer DiseaseNeuroinflammatory BiomarkersNeuroinflammatory Disease BiomarkersNeuroinflammatory MarkersRacial Disparities In DementiaVascular Dementia Biomarkers
INTRODUCTION: There remains an urgent need to identify preclinical pathophysiological mechanisms of Alzheimer's disease (AD) development in high-risk, racially diverse populations. We explored the relationship between cerebrospinal fluid (CSF) markers of vascular injury and neuroinflammation with AD biomarkers in middle-aged Black/African American (B/AA) and non-Hispanic White (NHW) participants. METHODS: Adults (45-65 years) with a parental history of AD were enrolled (n = 82). CSF and blood biomarkers were collected at baseline and year 2. RESULTS: CSF total tau (t-tau), phosphorylated tau (p-tau), and amyloid beta (Aβ)40 were elevated at year 2 compared to baseline. CSF soluble platelet-derived growth factor receptor β (sPDGFRβ) levels, a marker of pericyte injury, correlated positively with t-tau, p-tau, Aβ40 markers of vascular injury, and cytokines at baseline and year 2. CSF sPDGFRβ and tau were significantly lower in B/AA than NHW. DISCUSSION: Vascular dysfunction and neuroinflammation may precede cognitive decline and disease pathology in the very early preclinical stages of AD, and there are race-related differences in these relationships. HIGHLIGHTS: Cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers changed over 2 years in high-risk middle-aged adults. Markers of vascular dysfunction were associated with the CSF biomarkers amyloid beta and tau. AD biomarkers were lower in Black compared to non-Hispanic White individuals. Markers of vascular dysfunction were lower among Black individuals.
48
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Reisa A. Sperling, Paul Aisen, Laurel Beckett et al. · Alzheimer s & Dementia · 2011 · 7.1K citations · Full text
Medicine, Neurology, Neuroscience +17
Blood-Brain Barrier Breakdown in the Aging Human Hippocampus
Axel Montagne, Samuel Barnes, Melanie D. Sweeney et al. · Neuron · 2015 · 2.1K citations · Full text
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Daniel A. Nation, Melanie D. Sweeney, Axel Montagne et al. · Nature Medicine · 2019 · 1.7K citations
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Yang Shi, Kaoru Yamada, Shane A. Liddelow et al. · Nature · 2017 · 1.2K citations · Full text